iPSC models suggest that even if the effect of each individual genetic risk is small, the combined effect may initiate and accelerate the development of the pathology of sporadic diseases. In addition, even if SNP genotyping only indicates a small risk factor, it could be an important one, and modeling the pathological phenotype with iPSC technology could lead to a re-classification of sporadic diseases. Such re-classifications could have important implications for drug development. iPSC modeling has the potential to identify drug-responsive patient subgroups, including those with sporadic diseases, which should improve the quality of clinical trials119. A large cohort analysis with medical records and genome information combined with patient iPSCs is also expected and so iPSC-derived cells could provide a far more precise analysis of the individual genes and proteins involved in the disease.
